Zenas BioPharma Enabling patients with autoimmune diseases to reimagine life Corporate Presentation May 2025 1 Disclaimer FORWARD-LOOKING STATEMENTS: This presentation contains "forward-looking statements" which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts cont ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42270 Zenas BioPharma, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdicti ...

- Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 - Exhibit 99.1 Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates - Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter 20 ...

Core Insights - Zenas BioPharma is advancing its obexelimab program through multiple clinical trials, with topline results expected in late 2025 for Immunoglobulin G4-Related Disease and early Q4 2025 for Relapsing Multiple Sclerosis [1][2][4] Clinical Trials - The Phase 3 INDIGO trial for Immunoglobulin G4-Related Disease is the largest clinical trial conducted for this condition, with topline results anticipated around year-end 2025 [1][4] - The Phase 2 MoonStone trial for Relapsing Multiple Sclerosis is concluding enrollment, with topline results expected early in Q4 2025 [1][4] - The Phase 2 SunStone trial for Systemic Lupus Erythematosus is expected to complete enrollment by year-end 2025, with topline results anticipated in mid-2026 [1][4] Leadership Changes - The company has strengthened its leadership team with the appointments of Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer, and Haley Laken, Ph.D., as Chief Scientific Officer [1][4] Financial Position - As of March 31, 2025, Zenas BioPharma reported cash, cash equivalents, and investments totaling $314.2 million, which is expected to fund operations into Q4 2026 [1][11] - License and collaboration revenue for Q1 2025 was $10 million, attributed to a sublicense agreement with Zai Lab [11] - Research and development expenses increased to $34.9 million in Q1 2025 from $22.6 million in Q1 2024, primarily due to clinical development costs for obexelimab [11] - General and administrative expenses rose to $12.4 million in Q1 2025 from $4.9 million in Q1 2024, driven by increased personnel costs and pre-commercialization activities [11] Product Overview - Obexelimab is a bifunctional monoclonal antibody designed to inhibit B cell function without depleting them, targeting autoimmune diseases [3][7][9] - The drug has shown clinical activity in five completed trials involving 198 patients, providing initial proof of concept for its efficacy [8]

NEW YORK, May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=148435&from=4CLASS PERIOD: This lawsuit ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws, specifically regarding misleading statements about the company's financial status and operational funding [3][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $75,000 in Zenas to contact them for discussing legal options [1]. - A federal securities class action has been filed against Zenas, with a deadline of June 16, 2025, for investors to seek the role of lead plaintiff [3]. - The complaint alleges that Zenas materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [5]. Group 2: Class Action Details - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members [6]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6]. Group 3: Additional Information - Faruqi & Faruqi encourages anyone with information regarding Zenas' conduct, including whistleblowers and former employees, to contact the firm [7]. - For more information about the class action, interested parties can visit the firm's website or contact partner Josh Wilson directly [8].

WASHINGTON, D.C., May 13, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC issues the following update to investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) regarding the securities class action lawsuit filed in the U.S. District Court for the District of Massachusetts. Investors who purchased Zenas BioPharma shares pursuant and/or traceable to the company’s September 2024 initial public offering (IPO) have until June 16, 2025 to file a motion with the court to serve as lead plaintiff. [Click here ...

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud related to its September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased Zenas BioPharma securities linked to the company's IPO [2]. - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Zenas BioPharma have until June 16, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

NEW YORK, May 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zenas BioPharma, Inc. regarding a class action lawsuit related to misleading statements made during the company's initial public offering in September 2024 [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of individuals who purchased Zenas BioPharma securities during the specified class period [3]. - Allegations include that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false and misleading public statements [4]. - The deadline for shareholders to register for the class action is June 16, 2025, and there is no cost to participate [5]. Group 2: Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, emphasizing the importance of responsible business practices [6]. - The firm seeks recovery for investors who suffered losses due to misleading statements that artificially inflated the company's stock [6].